Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.36 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338628 | 0.83 | TSHR (0.62) | TSHRP2RY6P2RY2P2RY4FNTA | |
| SCHEMBL4232799 | 0.80 | ITPR3 (0.31) | — | |
| SCHEMBL2552260 | 0.80 | ITPR3 (0.31) | — | |
| SCHEMBL28036113 | 0.78 | ITPR3 (0.32) | — | |
| SCHEMBL29022797 | 0.74 | ITPR3 (0.34) | P2RY2P2RY4BTN3A1 | |
| SCHEMBL28555680 | 0.74 | TSHR (0.61) | TSHRFNTAFNTBPDPK1MTOR | |
| SCHEMBL10408383 | 0.74 | TSHR (0.66) | TSHRFNTAFNTBPDPK1MTOR | |
| SCHEMBL6749263 | 0.72 | TSHR (0.75) | TSHRFNTAFNTBPDPK1MTOR | |
| SCHEMBL6710152 | 0.72 | ITPR3 (0.33) | — | |
| SCHEMBL544344 | 0.72 | ITPR3 (0.37) | P2RY2P2RY4BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171394-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2014-06-19 | — | — | US | disclosed |
| US-20130190524-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | UNIVERSITE DE STRASBOURG (FR) | 2013-07-25 | — | — | US | disclosed |
| EP-2111226-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | Normoxys, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | UNIVERSITE DE STRASBOURG (FR) | 2008-08-21 | — | — | US | disclosed |
| WO-2008082658-A2 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NORMOXYS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200437-A1 | Polyphosphorylated inositol derivatives; allosteric effectors, cell signaling molecule analogs; hypoxia related diseases | PPIP5K2, IP6K1, IP6K3 | TSHR 2294/4885P2RY6 109/4885P2RY2 72/4885 |
| US-20130190524-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | PPIP5K2, ITPA, IPMK | TSHR 1898/4885P2RY6 109/4885P2RY2 122/4885 |
| US-20140171394-A1 | CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | PPIP5K2, ITPA, IPMK | TSHR 1898/4885P2RY6 109/4885P2RY2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.